|
US6100024A
(en)
|
1991-02-08 |
2000-08-08 |
Promega Corporation |
Methods and compositions for nucleic acid detection by target extension and probe amplification
|
|
US5298422A
(en)
|
1991-11-06 |
1994-03-29 |
Baylor College Of Medicine |
Myogenic vector systems
|
|
US5256555A
(en)
|
1991-12-20 |
1993-10-26 |
Ambion, Inc. |
Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
|
|
US5605798A
(en)
|
1993-01-07 |
1997-02-25 |
Sequenom, Inc. |
DNA diagnostic based on mass spectrometry
|
|
WO1995008626A1
(en)
|
1993-09-20 |
1995-03-30 |
The Regents Of The University Of Colorado |
Strategy for the production of rna from immobilized templates
|
|
US6096503A
(en)
|
1993-11-12 |
2000-08-01 |
The Scripps Research Institute |
Method for simultaneous identification of differentially expresses mRNAs and measurement of relative concentrations
|
|
FR2733762B1
(fr)
|
1995-05-02 |
1997-08-01 |
Genset Sa |
Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
|
|
US6251665B1
(en)
|
1997-02-07 |
2001-06-26 |
Cem Cezayirli |
Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
|
|
IL148922A0
(en)
|
1999-10-06 |
2002-09-12 |
Quark Biotech Inc |
Method for enrichment of natural antisense messenger rna
|
|
US20030165849A1
(en)
|
2000-11-28 |
2003-09-04 |
Biliang Zhang |
Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA
|
|
US20030154032A1
(en)
|
2000-12-15 |
2003-08-14 |
Pittman Debra D. |
Methods and compositions for diagnosing and treating rheumatoid arthritis
|
|
US8426194B2
(en)
|
2003-01-21 |
2013-04-23 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating VEGF expression
|
|
GB0316089D0
(en)
|
2003-07-09 |
2003-08-13 |
Xo Bioscience Ltd |
Differentiation method
|
|
US20140142290A1
(en)
|
2003-08-01 |
2014-05-22 |
Life Technologies Corporation |
Compositions and methods for preparing short rna molecules and other nucleicacids
|
|
EP2216415B2
(en)
*
|
2003-08-01 |
2017-01-04 |
Life Technologies Corporation |
Methods for preparing short RNA molecules
|
|
US20050287539A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Emmanuel Labourier |
Methods and compositions for preparing capped RNA
|
|
US20080220471A1
(en)
|
2005-07-27 |
2008-09-11 |
Genentech, Inc. |
Vectors and Methods Using Same
|
|
EP4174179B1
(en)
|
2005-08-23 |
2025-05-07 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
US9012219B2
(en)
*
|
2005-08-23 |
2015-04-21 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
|
CA2649325C
(en)
|
2006-04-14 |
2019-01-08 |
Epicentre Technologies Corporation |
Kits and methods for generating 5' capped rna
|
|
US8268586B2
(en)
|
2006-12-21 |
2012-09-18 |
Novozymes, Inc. |
Modified messenger RNA stabilizing sequences for expressing genes in bacterial cells
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2011005799A2
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
BR112012013875B8
(pt)
|
2009-12-07 |
2020-06-23 |
Person Anthony |
método in vitro para reprogramar células somáticas humanas ou de outros mamíferos para células tronco pluripotentes induzidas (células ips ou ipscs) e composição
|
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US20130189742A1
(en)
|
2010-09-21 |
2013-07-25 |
Jacques Rohayem |
Microwave-Driven RNA Polymerization by RNA Polymerases of Caliciviruses
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
WO2012068383A2
(en)
|
2010-11-19 |
2012-05-24 |
The Regents Of The University Of Michigan |
ncRNA AND USES THEREOF
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
US20140206752A1
(en)
|
2011-05-17 |
2014-07-24 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US20140378538A1
(en)
|
2011-12-14 |
2014-12-25 |
Moderma Therapeutics, Inc. |
Methods of responding to a biothreat
|
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2013096709A2
(en)
|
2011-12-21 |
2013-06-27 |
modeRNA Therapeutics |
Methods of increasing the viability or longevity of an organ or organ explant
|
|
LT3144389T
(lt)
*
|
2011-12-30 |
2018-08-10 |
Cellscript, Llc |
In vitro susintetintos viengrandės rnr gavimas ir panaudojimas įvedimui į žinduolio ląsteles, siekiant sužadinti biologinį arba biocheminį poveikį
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
EP2931914A4
(en)
|
2012-12-13 |
2016-08-17 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR CHANGING THE CELL PHENOTYPE
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
TR201901310T4
(tr)
|
2013-03-14 |
2019-02-21 |
Translate Bio Inc |
Mesajcı RNA'nın saflaştırılması yöntemleri.
|
|
AU2014239250A1
(en)
|
2013-03-14 |
2015-08-27 |
Shire Human Genetic Therapies, Inc. |
Quantitative assessment for cap efficiency of messenger RNA
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US10590161B2
(en)
|
2013-03-15 |
2020-03-17 |
Modernatx, Inc. |
Ion exchange purification of mRNA
|
|
CN105283548A
(zh)
|
2013-03-15 |
2016-01-27 |
葛兰素史密斯克莱生物公司 |
Rna纯化方法
|
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
|
EP4279610A3
(en)
|
2013-03-15 |
2024-01-03 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
|
US20160017313A1
(en)
|
2013-03-15 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
WO2014144039A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
SI3019619T1
(sl)
|
2013-07-11 |
2021-12-31 |
Modernatx, Inc. |
Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
US20170173128A1
(en)
|
2013-12-06 |
2017-06-22 |
Moderna TX, Inc. |
Targeted adaptive vaccines
|
|
KR20160132113A
(ko)
|
2014-03-20 |
2016-11-16 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
확장된 기질 범위 및 증진된 전사 수율을 갖는 t7 rna 폴리머라제 변이체
|
|
ES3009962T3
(en)
|
2014-04-23 |
2025-03-31 |
Modernatx Inc |
Nucleic acid vaccines
|
|
ES2727776T3
(es)
|
2014-06-10 |
2019-10-18 |
Curevac Ag |
Método para mejorar la producción de ARN
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
AU2015289573A1
(en)
|
2014-07-17 |
2017-02-02 |
Modernatx, Inc |
Terminal modifications of polynucleotides
|
|
EP3247363A4
(en)
|
2015-01-21 |
2018-10-03 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
SG11201708681SA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Method for in vitro transcription using an immobilized restriction enzyme
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
WO2017011773A2
(en)
|
2015-07-15 |
2017-01-19 |
Modernatx, Inc. |
Codon-optimized nucleic acids encoding antibodies
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
US20190008887A1
(en)
|
2015-07-30 |
2019-01-10 |
ModernaTX Inc. |
Multimeric mrna
|
|
US20180237849A1
(en)
|
2015-08-17 |
2018-08-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
US10849920B2
(en)
|
2015-10-05 |
2020-12-01 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
MA46317A
(fr)
|
2015-10-22 |
2019-08-07 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
JP2018532777A
(ja)
|
2015-10-22 |
2018-11-08 |
モデルナティーエックス， インコーポレイテッド |
癌ワクチン
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
CN118846026A
(zh)
|
2015-10-22 |
2024-10-29 |
摩登纳特斯有限公司 |
广谱流感病毒疫苗
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
PE20181529A1
(es)
|
2015-10-22 |
2018-09-26 |
Modernatx Inc |
Vacunas de acido nucleico para el virus varicela-zoster (vzv)
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
US20180303929A1
(en)
|
2015-10-22 |
2018-10-25 |
Moderna TX, Inc. |
Herpes simplex virus vaccine
|
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
JP7065036B2
(ja)
|
2015-12-17 |
2022-05-11 |
モダーナティエックス・インコーポレイテッド |
メチルマロニルＣｏＡムターゼをコードするポリヌクレオチド
|
|
SMT202200252T1
(it)
|
2015-12-22 |
2022-07-21 |
Modernatx Inc |
Composti e composizioni per il rilascio intracellulare di agenti
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
CN108779446B
(zh)
|
2016-01-13 |
2023-04-21 |
新英格兰生物实验室公司 |
T7 rna聚合酶的热稳定变体
|
|
US20210206818A1
(en)
|
2016-01-22 |
2021-07-08 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
MA45050A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
JP2019519601A
(ja)
|
2016-05-18 |
2019-07-11 |
モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． |
急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
|
|
WO2017201317A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
WO2017201328A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
|
|
MA45053A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
CN109195621A
(zh)
|
2016-05-18 |
2019-01-11 |
莫得纳特斯公司 |
编码白细胞介素12(il12)的多核苷酸及其用途
|
|
KR102533456B1
(ko)
|
2016-05-18 |
2023-05-17 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
WO2017201348A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
MA45036A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
|
|
JP2019525901A
(ja)
|
2016-06-14 |
2019-09-12 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
脂質ナノ粒子の安定化製剤
|
|
CN106244608B
(zh)
|
2016-08-08 |
2019-10-25 |
中国科学技术大学 |
诱导的t7 rna聚合酶
|
|
WO2018053209A1
(en)
|
2016-09-14 |
2018-03-22 |
Modernatx, Inc. |
High purity rna compositions and methods for preparation thereof
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
WO2018081462A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Methods and compositions for rna mapping
|
|
RU2765874C2
(ru)
|
2016-10-26 |
2022-02-04 |
МОДЕРНАТиЭкс, ИНК. |
Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN110167587A
(zh)
|
2016-11-11 |
2019-08-23 |
摩登纳特斯有限公司 |
流感疫苗
|
|
US11103578B2
(en)
|
2016-12-08 |
2021-08-31 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
US11384352B2
(en)
|
2016-12-13 |
2022-07-12 |
Modernatx, Inc. |
RNA affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
EP3576780A1
(en)
|
2017-02-01 |
2019-12-11 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
KR20190120233A
(ko)
|
2017-02-01 |
2019-10-23 |
모더나티엑스, 인크. |
Rna 암 백신
|
|
WO2018144778A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Polynucleotide secondary structure
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
US20200368162A1
(en)
|
2017-02-24 |
2020-11-26 |
Modernatx, Inc. |
Nucleic Acid-Based Therapy of Muscular Dystrophies
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
EP3609534A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
WIDE SPECTRUM INFLUENZA VIRUS VACCINE
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
SI3596041T1
(sl)
|
2017-03-15 |
2023-02-28 |
Modernatx, Inc. |
Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
US20200038499A1
(en)
|
2017-03-22 |
2020-02-06 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
US20200054737A1
(en)
|
2017-04-26 |
2020-02-20 |
Modema TX, Inc. |
Herpes simplex virus vaccine
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
EP3645711A4
(en)
|
2017-06-30 |
2021-04-21 |
Codexis, Inc. |
T7 RNA POLYMERASE VARIANTS
|
|
MA49634A
(fr)
|
2017-07-21 |
2020-05-27 |
Modernatx Inc |
Arnm modifié codant pour une propionyl-coa-carboxylase et utilisations associées
|
|
EP3668971B8
(en)
|
2017-08-18 |
2024-05-29 |
ModernaTX, Inc. |
Rna polymerase variants
|
|
EP3668977A4
(en)
|
2017-08-18 |
2021-04-21 |
Modernatx, Inc. |
HPLC ANALYTICAL PROCESSES
|
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
JP7308000B2
(ja)
|
2017-10-31 |
2023-07-13 |
モデルナティエックス インコーポレイテッド |
Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａを送達するための脂質ナノ粒子
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
EP3713601A4
(en)
|
2017-11-21 |
2022-03-09 |
Modernatx, Inc. |
VACCINES AGAINST EPSTEIN-BARR VIRUS
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
KR20210038886A
(ko)
|
2018-06-27 |
2021-04-08 |
모더나티엑스, 인크. |
개인화된 암 백신 에피토프 선택
|
|
WO2020056370A1
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
CA3118947A1
(en)
|
2018-11-07 |
2020-05-14 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
CA3128215A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
CN113795579A
(zh)
|
2019-02-20 |
2021-12-14 |
摩登纳特斯有限公司 |
用于共转录加帽的rna聚合酶变体
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
KR20210149727A
(ko)
|
2019-03-11 |
2021-12-09 |
모더나티엑스, 인크. |
유가식(fed-batch) 시험관내 전사 공정
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
MA56060A
(fr)
|
2019-05-31 |
2022-04-06 |
Modernatx Inc |
Dosage de lymphocytes t ayant subi une expansion
|
|
CN114269918A
(zh)
|
2019-08-14 |
2022-04-01 |
摩登纳特斯有限公司 |
用于纯化体外转录的下游产物的方法
|
|
AU2020346041A1
(en)
|
2019-09-11 |
2022-03-31 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CN120423969A
(zh)
|
2019-09-19 |
2025-08-05 |
摩登纳特斯有限公司 |
用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
|
|
WO2021055811A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Cap guides and methods of use thereof for rna mapping
|
|
US20210217484A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Variational autoencoder for biological sequence generation
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
US20230338506A1
(en)
|
2020-01-30 |
2023-10-26 |
Modernatx, Inc. |
Respiratory virus immunizing compositions
|
|
JP2023513043A
(ja)
|
2020-01-31 |
2023-03-30 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子を調製する方法
|
|
AU2021215938A1
(en)
|
2020-02-07 |
2022-09-01 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
EP4149484A4
(en)
|
2020-05-15 |
2024-10-02 |
ModernaTX, Inc. |
RNA FORMULATIONS FOR HIGH VOLUME DELIVERY
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
US20230190761A1
(en)
|
2020-05-21 |
2023-06-22 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
|
CA3185855A1
(en)
|
2020-06-05 |
2021-12-09 |
Modernatx, Inc. |
Bacterial strains for dna production
|
|
CA3189854A1
(en)
|
2020-08-06 |
2022-02-10 |
Modernatx, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4217371A1
(en)
|
2020-09-25 |
2023-08-02 |
ModernaTX, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
WO2022150717A1
(en)
|
2021-01-11 |
2022-07-14 |
Modernatx, Inc. |
Seasonal rna influenza virus vaccines
|
|
CA3208486A1
(en)
|
2021-01-15 |
2022-07-21 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
CA3208303A1
(en)
|
2021-01-15 |
2022-07-21 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
CA3212664A1
(en)
|
2021-03-05 |
2022-09-09 |
Modernatx, Inc. |
Vlp enteroviral vaccines
|
|
US20240299531A1
(en)
|
2021-03-15 |
2024-09-12 |
Moderna TX, Inc |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
CN117677389A
(zh)
|
2021-03-26 |
2024-03-08 |
摩登纳特斯有限公司 |
百日咳疫苗
|
|
TW202304944A
(zh)
|
2021-03-31 |
2023-02-01 |
美商現代公司 |
用於產生ｍＲＮＡ之三核苷酸及四核苷酸帽的合成
|
|
WO2022212191A1
(en)
|
2021-04-01 |
2022-10-06 |
Modernatx, Inc. |
Mucosal expression of antibody structures and isotypes by mrna
|
|
AU2022249357A1
(en)
|
2021-04-01 |
2023-10-12 |
Modernatx, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
US20240216500A1
(en)
|
2021-04-13 |
2024-07-04 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
JP2024514183A
(ja)
|
2021-04-13 |
2024-03-28 |
モデルナティエックス インコーポレイテッド |
エプスタイン－バーウイルスｍＲＮＡワクチン
|
|
WO2022221336A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory syncytial virus mrna vaccines
|
|
AU2022258463A1
(en)
|
2021-04-14 |
2023-11-23 |
Modernatx, Inc. |
Influenza-coronavirus combination vaccines
|
|
EP4326227A1
(en)
|
2021-04-23 |
2024-02-28 |
ModernaTX, Inc. |
Stabilized formulations
|
|
WO2022226318A1
(en)
|
2021-04-23 |
2022-10-27 |
Modernatx, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
|
EP4329731A1
(en)
|
2021-04-29 |
2024-03-06 |
ModernaTX, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
US20240293534A1
(en)
|
2021-06-14 |
2024-09-05 |
Modernatx, Inc. |
Coronavirus glycosylation variant vaccines
|
|
WO2022266010A1
(en)
|
2021-06-14 |
2022-12-22 |
Modernatx, Inc. |
Mrna vaccines encoding flexible coronavirus spike proteins
|
|
WO2022266389A1
(en)
|
2021-06-17 |
2022-12-22 |
Modernatx, Inc. |
Alternative rna purification strategies
|
|
WO2023283642A2
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus concatemeric vaccines
|
|
EP4366768A4
(en)
|
2021-07-09 |
2025-05-21 |
ModernaTX, Inc. |
Pan-human coronavirus vaccines
|
|
WO2023283645A1
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus domain vaccines
|
|
EP4381059A1
(en)
|
2021-08-02 |
2024-06-12 |
ModernaTX, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
|
US20250281418A1
(en)
|
2021-08-11 |
2025-09-11 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
|
TW202321446A
(zh)
|
2021-08-13 |
2023-06-01 |
美商現代公司 |
多管柱層析ｍＲＮＡ純化
|
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
|
WO2023069900A1
(en)
|
2021-10-18 |
2023-04-27 |
Modernatx, Inc. |
Custom bacterial strain for recombinant protein production
|
|
US20250011798A1
(en)
|
2021-10-18 |
2025-01-09 |
Modernatx, Inc. |
Markerless dna production
|
|
US20250231165A1
(en)
|
2021-10-20 |
2025-07-17 |
Modernatx, Inc. |
Drug product surrogate solutions
|
|
US20250362278A1
(en)
|
2021-11-01 |
2025-11-27 |
Modernatx, Inc. |
Mass spectrometry of mrna
|
|
US20240425902A1
(en)
|
2021-11-05 |
2024-12-26 |
Moderna TX, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
WO2023107999A2
(en)
|
2021-12-08 |
2023-06-15 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
|
WO2023114307A1
(en)
|
2021-12-15 |
2023-06-22 |
Modernatx, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
|
WO2023132885A1
(en)
|
2022-01-04 |
2023-07-13 |
Modernatx, Inc. |
Methods of purifying dna for gene synthesis
|
|
EP4463545A1
(en)
|
2022-01-14 |
2024-11-20 |
ModernaTX, Inc. |
In vitro transcription dna purification and recycling
|
|
JP2025506416A
(ja)
|
2022-02-03 |
2025-03-11 |
モデルナティエックス インコーポレイテッド |
ｍＲＮＡ精製のための連続的沈殿
|
|
EP4475882A1
(en)
|
2022-02-09 |
2024-12-18 |
ModernaTX, Inc. |
Mucosal administration methods and formulations
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
WO2023201204A1
(en)
|
2022-04-11 |
2023-10-19 |
Modernatx, Inc. |
Detection of mrna purity in a mixture
|
|
JP2025513874A
(ja)
|
2022-04-14 |
2025-04-30 |
モデルナティエックス インコーポレイテッド |
Ｒｎａポリメラーゼバリアント
|
|
EP4508069A1
(en)
|
2022-04-15 |
2025-02-19 |
ModernaTX, Inc. |
Ribosomal engagement potency assay
|
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
|
US20250340586A1
(en)
|
2022-05-17 |
2025-11-06 |
Modernatx, Inc. |
Preparation of highly concentrated mrna
|
|
WO2023250119A1
(en)
|
2022-06-24 |
2023-12-28 |
Modernatx, Inc. |
Methods of producing rna
|
|
WO2024010993A1
(en)
|
2022-07-06 |
2024-01-11 |
Modernatx, Inc. |
Primer design for cell-free dna production
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
WO2024026005A1
(en)
|
2022-07-28 |
2024-02-01 |
Modernatx, Inc. |
Methods of rna purification
|
|
EP4565694A1
(en)
|
2022-08-01 |
2025-06-11 |
ModernaTX, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
EP4612301A1
(en)
|
2022-11-03 |
2025-09-10 |
ModernaTX, Inc. |
Chemical stability of mrna
|
|
EP4630397A1
(en)
|
2022-12-08 |
2025-10-15 |
ModernaTX, Inc. |
Ionizable lipids with malonate tails
|
|
EP4648793A1
(en)
|
2023-01-11 |
2025-11-19 |
ModernaTX, Inc. |
Personalized cancer vaccines
|
|
EP4658306A1
(en)
|
2023-01-30 |
2025-12-10 |
ModernaTX, Inc. |
Epstein-barr virus mrna vaccines
|